

Special Issue

Silver and Gold Compounds as Antibiotics

Message from the Guest Editors

Bacterial infections are a continuous threat to human health and one of the most important challenges in medicine today. The healthcare sector is facing a totally new challenge when it comes to dealing with the design and development of new antibiotics. Silver and gold salts have traditionally been administered to microbial infections. It is, therefore, essential to design new silver or gold compounds able to overcome the bacterial resistance of already known antibiotics. Moreover, promising antibacterial metal compounds such as those of silver or gold aim to resist the development of multidrug resistant bacteria, and this is a research and financial issue of great importance. This Special Issue of MDPI *Antibiotics* entitled “Silver and Gold Compounds As Antibiotics” aims to provide an overview of this increasingly diverse field, presenting recent developments and the latest research with particular emphasis on the role of silver or gold compounds as antibiotics. Readers of this Special Issue will gain a broader knowledge of antimicrobial metal compounds.

Guest Editors

Prof. Dr. Sotiris K Hadjikakou

Section of Inorganic and Analytical Chemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece

Dr. Christina N. Banti

Section of Inorganic and Analytical Chemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece

Deadline for manuscript submissions

closed (31 January 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/101026

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)